Clinical studies of lactobacilli showing inhibitory activity against H. pylori infection
| Bacteria | Dose | Pathology | Ref. (Design) |
|---|---|---|---|
| L. johnsonii La1 | > 107 CFU/mL (80 mL) | Asymptomatic H. pylori infection | 173(double-blind, randomised, controlled clinical study) |
| L. gasseri OLL2716 | 1–1.4×107 CFU/g (90 g) | H. pylori infection | 174(open study) |
| Enterolactis® (L. casei subsp casei DG + Vitamin B1, B2 and B6) | 1.6×109 CFU | H. pylori infection | 182(open study) |
| Actimel®: (L. acidophilus HY2177, L. casei HY2743, B. longum HY8001 and St. thermophilus B-1) | 5×109 CFU (total) | H. pylori infection | 184(open study) |
| L. reuteri ATCC 55730 | 1×108 CFU | H. pylori infection | 185(open study) |
| Will yogurt (L. acidophilus HY2177, L. casei HY2743, B. longum HY8001 and St. thermophilus B-1) | ≥1×105 CFU ≥1×105 CFU ≥1×106 CFU ≥1×108 CFU | H. pylori infection | 186(randomised triple-therapy study) |
| AB-yogurt (L. acidophilus La5 and B. lactis Bb12) | 107 CFU/mL (230 mL) (of each) | H. pylori infection | 175(open study) |
| Genefilus F19© (L. paracasei sub. paracasei F19) | 12×109 CFU | H. pylori infection-related gastroesophageal reflux | 177(randomised, double-blind, placebo-controlled study) |
| L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) | 1×108 CFU (total) | H. pylori infection | 187(prospective, double-blind, randomised, placebo-controlled study) |
| L. gasseri OLL2716 | ≥109 CFU | H. pylori infection | 188(randomised, controlled clinical study) |
| L. brevis CD2 | 20×109 CFU | H. pylori infection | 189(open study) |